Effectiveness of oseltamivir in the prevention and treatment of influenza in children

Cover Page

Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Oseltamivir is an inhibitor of influenza virus neuraminidase and suppresses the reproduction of pathogen subtypes A and B. The drug contributes to reduction of the duration of influenza symptoms (febrile, headache, cough), and also reduces the incidence of complications (otitis media, etc.) in children aged 0–18 years. The effectiveness of oseltamivir has not been confirmed in influenza against the background of bronchial asthma and/or the drug is prescribed later than 48 hours from the onset of the disease. The drug is an independent means of chemoprophylaxis of influenza in persons who have been in contact with infected people.

Full Text

Restricted Access

About the authors

Eleonora B. Belan

Volgograd State Medical University, Department of Immunology and Allergology

Author for correspondence.
Email: belan.eleonora@yandex.ru
ORCID iD: 0000-0003-2674-4289

Dr. Sci. (Med.), Professor, Head of the Department of Immunology and Allergology

Russian Federation, Volgograd

E. M. Nikiforova

Volgograd State Medical University, Department of Immunology and Allergology

Email: belan.eleonora@yandex.ru
Russian Federation, Volgograd

References

  1. Кардаш О.Ф. Осельтамивир: применение при гриппе. Рецепт. 2020;23(1):116–20. [Kardash O.F. Oseltamivir: use in influenza. Retsept. 2020;23(1):116–20. (In Russ.)]. doi: 10.34883/PI.2020.23.1.012.
  2. Методические рекомендации «Грипп и другие ОРВИ в период продолжающейся пандемии COVID-19: профилактика и лечение» (утв. Федеральным медико-биологическим агентством 10 ноября 2022 г.) [Guidelines “Influenza and other acute respiratory viral infections during the ongoing COVID-19 pandemic: prevention and treatment” (approved by the Federal Medical and Biological Agency on November 10, 2022). (In Russ.)].
  3. Касымова Е.Б., Башкина О.А., Галимзянов Х.М. и др. Оптимизация фармакотерапии у детей с острой Эпштейна–Барр вирусной инфекцией. Экспериментальная и клиническая фармакология. 2014;77(1):26–9. [Kasymova E.B., Bashkina O.A., Galimzyanov KH.M., et al. Optimization of pharmacotherapy in children with acute Epstein-Barr virus infection. Ehksperimental’naya i klinicheskaya farmakologiya. 2014;77(1):26–9. (In Russ.)].
  4. Li G., Yue T., Zhang P., et al. Drug Discovery of Nucleos(t)ide Antiviral Agents: Dedicated to Prof. Dr. Erik De Clercq on Occasion of His 80th Birthday. Molecul. 2021;26(4):923. doi: 10.3390/molecules26040923.
  5. Stiver G. The treatment of influenza with antiviral drugs. CMAJ. 2003;168(1):49–56.
  6. Петров В.И., Белан Э.Б. Противовирусные средства. М., 2012. 224 с. [Petrov V.I., Belan E.B. Antivirals. M., 2012. 224 р. (In Russ.)].
  7. Collins P.J., Haire L.F., Lin Y.P., et al. Crystal structures of oseltamivir-resistant influenza virus neuraminidase mutants. Nature. 2008;453(7199):1258–61. doi: 10.1038/nature06956.
  8. Hanpaibool C., Leelawiwat M., Takahashi K., Rungrotmongkol T. Source of oseltamivir resistance due to single E119D and double E119D/H274Y mutations in pdm09H1N1 influenza neuraminidase. J Comput Aided Mol Des. 2020;34(1):27–37. doi: 10.1007/s10822-019-00251-7.
  9. Macesic N., Laplante J.M., Aaron J.G., et al. Baloxavir treatment of oseltamivir-resistant influenza A/H1pdm09 in two immunocompromised patients. Transpl Infect Dis. 2021;23(3):e13542. doi: 10.1111/tid.13542.
  10. McKimm-Breschkin J., Trivedi T., Hampson A., et al. Neuraminidase sequence analysis and susceptibilities of influenza virus clinical isolates to zanamivir and oseltamivir. Antimicrob Agents Chemother. 2003;47(7):2264–72. doi: 10.1128/AAC.47.7.2264-2272.2003.
  11. Kiso M., Mitamura K., Sakai-Tagawa Y., et al. Resistant influenza A viruses in children treated with oseltamivir: descriptive study. Lancet. 2004;364(9436):759–65. doi: 10.1016/S0140-6736(04)16934-1. [PMID: 15337401].
  12. Tappenden P., Jackson R., Cooper K., et al. Amantadine, oseltamivir and zanamivir for the prophylaxis of influenza (including a review of existing guidance no. 67): a systematic review and economic evaluation. Health Technol Assess. 2009;13(11):iii, ix–xii, 1–246. doi: 10.3310/hta13110.
  13. Глебова Т.И., Кливлеева Н.Г., Лукманова Г.В. и др. Чувствительность к противовирусным препаратам штаммов вируса гриппа, выделенных в различных регионах Казахстана в 2018–2019 гг. Инфекция и иммунитет. 2021;11(6):1159–66. [Glebova T.I., Klivleyeva N.G., Lukmanova G.V., et al. 2018–2019 antiviral drug sensitivity of the influenza virus strains isolated from various regions of Kazakhstan. Infektsiya i immunitet=Rus J Infect Immun. 2021;11(6):1159–66. doi: 10.15789/2220-7619-ADS-1497. (In Russ.)].
  14. Осельтамивир. Официальная инструкция, зарегистрированная Минздравом РФ. [Oseltamivir. Official instructions registered by the Ministry of Health of the Russian Federation.https://grls.rosminzdrav.ru/GRLS.aspx?RegNumber=%d0%9b%d0%9f-005210&MnnR=&lf=&TradeNmR=&OwnerName=&MnfOrg=&MnfOrgCountry=&isfs=0®type=1%2c6&pageSize=10&order=Registered&orderType=desc&pageNum=1. (In Russ.)].
  15. Whitley R.J., Hayden F.G., Reisinger K.S., et al. Oral oseltamivir treatment of influenza in children. Pediatr Infect Dis J. 2001 Feb;20(2):127-33. doi: 10.1097/00006454-200102000-00002. Erratum in: Pediatr Infect Dis J. 2001;20(4):421.
  16. Jefferson T., Jones M., Doshi P., et al. Oseltamivir for influenza in adults and children: systematic review of clinical study reports and summary of regulatory comments. BMJ. 2014;348:g2545. doi: 10.1136/bmj.g2545.
  17. Lee J.J., Smith M., Bankhead C., et al. Oseltamivir and influenza-related complications in children: a retrospective cohort in primary care. Eur Respir J. 2020;56(5):1902246. doi: 10.1183/13993003.02246-2019.
  18. Malosh R.E., Martin E.T., Heikkinen T., et al. Efficacy and Safety of Oseltamivir in Children: Systematic Review and Individual Patient Data Meta-analysis of Randomized Controlled Trials. Clin Infect Dis. 2018;66(10):1492–500. doi: 10.1093/cid/cix1040.
  19. Qin J., Lin J., Zhang X., et al. Evaluation of the Clinical Effectiveness of Oseltamivir for Influenza Treatment in Children. Front Pharmacol. 2022;13:849545. doi: 10.3389/fphar.2022.849545.
  20. Mitamura K., Sugaya N., Nirasawa M., et al. [Effectiveness of oseltamivir treatment against influenza type A and type B infection in children]. Kansenshogaku Zasshi. 2002;76(11):946–52. Japanese. doi: 10.11150/kansenshogakuzasshi1970.76.946.
  21. Mattila J.M., Vuorinen T., Waris M., et al. Oseltamivir treatment of influenza A and B infections in infants. Influenza Other Respir Virus. 2021;15(5):618–24. doi: 10.1111/irv.12862.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download
2. Fig. 1

Download (435KB)
Indexing metadata
3. Fig. 2

Download (301KB)
Indexing metadata
4. Fig. 3

Download (477KB)
Indexing metadata
5. Fig. 4

Download (337KB)
Indexing metadata

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies